After 12 weeks, compared to the start of the study, while the placebo group had not improved, the L-carnitine group had lower levels of two key factors in heart disease: 41 percent lower levels of C-reactive protein—a sign of systemic inflammation—and a significant decrease in plasma fibrinogen, an inflammation-related blood-clotting agent.